New Home-Mid Content


The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.

We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.

More about the Centre


With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.

More about the Registry


The King’s Thrombosis Centre runs this training course twice a year, which was developed to meet the educational needs of healthcare professionals involved in anticoagulation management. Click here to download an application form and agenda.

For further information, contact Dr Raj Patel


After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click the image to access the site.

Latest News

  • Anticoagulation news items. Week commencing 8th July 2019
    Optimal route for administering tranexamic acid in primary unilateral total hip arthroplasty: Results from a multicenter cohort study British Journal of Clinical Pharmacology Data collection from 7,667 total hip arthroplasties…
  • Anticoagulation news items. Week commencing 1st July 2019
    Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation JAMA Cardiology In this cohort study of 10,137 patients with…
  • Anticoagulation news items. Week commencing 24th June 2019
    Extended Anticoagulation for VTE: A Systematic Review and Meta-Analysis Chest Review of 16 studies (n=12,458) found DOACs linked to decrease in overall (risk ratio 0.48;95% CI;0.27-0.86;p=0.01) and VTE-related (0.36;0.15-0.89;p=0.03) mortality…